BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26059451)

  • 1. STAT5A regulates DNMT3A in CD34(+)/CD38(-) AML cells.
    Takeuchi A; Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leuk Res; 2015 Aug; 39(8):897-905. PubMed ID: 26059451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
    Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
    Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Takeuchi A; Nobumoto A; Tsuda M; Yokoyama A
    Leukemia; 2015 Dec; 29(12):2296-306. PubMed ID: 26260387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior.
    Tang JZ; Zuo ZH; Kong XJ; Steiner M; Yin Z; Perry JK; Zhu T; Liu DX; Lobie PE
    Endocrinology; 2010 Jan; 151(1):43-55. PubMed ID: 19966185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
    Tagde A; Rajabi H; Stroopinsky D; Gali R; Alam M; Bouillez A; Kharbanda S; Stone R; Avigan D; Kufe D
    Oncotarget; 2016 Jun; 7(26):38974-38987. PubMed ID: 27259275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gfi-1 is the transcriptional repressor of SOCS1 in acute myeloid leukemia cells.
    Lee MC; Kuo YY; Chou WC; Hou HA; Hsiao M; Tien HF
    J Leukoc Biol; 2014 Jan; 95(1):105-15. PubMed ID: 24018353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis.
    Kaymaz BT; Selvi N; Gündüz C; Aktan C; Dalmızrak A; Saydam G; Kosova B
    Ann Hematol; 2013 Jan; 92(2):151-62. PubMed ID: 23053176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
    Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
    Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.
    Sun Q; So CC; Yip SF; Wan TS; Ma SK; Chan LC
    Leuk Res; 2008 Sep; 32(9):1374-81. PubMed ID: 18372040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression.
    Zhang Q; Wang HY; Liu X; Wasik MA
    Nat Med; 2007 Nov; 13(11):1341-8. PubMed ID: 17922009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.